We report the case of a 46-year-old female who showed excellent clinical outcomes after palliative 3rd line capecitabine monotherapy followed by 2nd liver metastasectomy. She had been diagnosed with colon cancer with liver metastasis and initially treated with synchronous colectomy and liver metastasectomy. But she experienced immediate relapse in liver and received palliative 1st line FOLFIRI and 2nd line FOLFOX, both of which failed to show responses. Capecitabine alone as palliative 3rd line treatment did show clinical response in this patient, indeed, and she received 2nd liver metastasectomy which revealed pathologic complete response. In this report, we intended to emphasize that response to chemotherapy could be an important factor i...
Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is assoc...
Background: We report the histopathological results of a novel "inversed” strategy designed to manag...
Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has pr...
Introduction: The prognostic outcome following progression after palliative first-line treatment f...
The clinical management of frail, elderly patients affected by colorectal cancer (CRC) remains a sub...
The complete pathological response after primary chemotherapy could represent an important prognosti...
KEY CLINICAL MESSAGE: The cost of treating metastatic colorectal cancer has increased significantly ...
Three patients, 61, 58 and 63 years old, presented with non-resectable liver metastases from colorec...
The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the f...
PURPOSE: Complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherap...
PURPOSE: Complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherap...
: In fit metastatic colorectal cancer (MCRC), multidisciplinary treatment strategy integrating inten...
Objective: To evaluate the efficacy and toxicity of capecitabine maintenance therapy in metastatic c...
SUMMARY Introduction Colorectal cancer is the third most common cancer and one of the leading causes...
none7noThe array of tools currently available and the aim of treatment make choosing the best therap...
Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is assoc...
Background: We report the histopathological results of a novel "inversed” strategy designed to manag...
Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has pr...
Introduction: The prognostic outcome following progression after palliative first-line treatment f...
The clinical management of frail, elderly patients affected by colorectal cancer (CRC) remains a sub...
The complete pathological response after primary chemotherapy could represent an important prognosti...
KEY CLINICAL MESSAGE: The cost of treating metastatic colorectal cancer has increased significantly ...
Three patients, 61, 58 and 63 years old, presented with non-resectable liver metastases from colorec...
The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the f...
PURPOSE: Complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherap...
PURPOSE: Complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherap...
: In fit metastatic colorectal cancer (MCRC), multidisciplinary treatment strategy integrating inten...
Objective: To evaluate the efficacy and toxicity of capecitabine maintenance therapy in metastatic c...
SUMMARY Introduction Colorectal cancer is the third most common cancer and one of the leading causes...
none7noThe array of tools currently available and the aim of treatment make choosing the best therap...
Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is assoc...
Background: We report the histopathological results of a novel "inversed” strategy designed to manag...
Background/Purpose: The median survival for patients with metastatic colorectal cancer (mCRC) has pr...